Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated ou...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Med Sci
Hlavní autoři: Krasniqi, Eriseld, Pizzuti, Laura, Valerio, Maria Rosaria, Capomolla, Elisabetta, Botti, Claudio, Sanguineti, Giuseppe, Marchetti, Paolo, Anselmi, Elisabetta, Tomao, Silverio, Giordano, Antonio, Ficorella, Corrado, Cannita, Katia, Livi, Lorenzo, Meattini, Icro, Mauri, Maria, Greco, Filippo, Veltri, Enzo Maria, Michelotti, Andrea, Moscetti, Luca, Giotta, Francesco, Lorusso, Vito, Paris, Ida, Tomao, Federica, Santini, Daniele, Tonini, Giuseppe, Villa, Alice, Gebbia, Vittorio, Gamucci, Teresa, Ciliberto, Gennaro, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Vici, Patrizia
Médium: Artigo
Jazyk:Inglês
Vydáno: Ivyspring International Publisher 2021
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8040412/
https://ncbi.nlm.nih.gov/pubmed/33859534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijms.54996
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky